MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
BioCryst Pharmaceuticals DSO Ratio 2011-2026 | BCRX
Annual DSO Ratio BioCryst Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 55.1 | 35.9 | 6.91 | 11.9 | 311 | 166 | 75.9 | 88.6 | 121 | 47.2 | 255 | 44.5 | 63.3 | 141 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 311 | 6.91 | 102 |
Quarterly DSO Ratio BioCryst Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 52.2 | 51.5 | 54.1 | - | 1.22 | 2.38 | 2.89 | - | 1.97 | 1.75 | 6.21 | - | 1.82 | 1.35 | 3.58 | - | 10.9 | 13.7 | 40.1 | 187 | 123 | 262 | 287 | 50.9 | 1.14 K | 1.4 K | 205 | 144 | 269 | 31.4 | 119 | 143 | 63.7 | 180 | 72 | 89.1 | 103 | 167 | 142 | 124 | 51.9 | 22 | 67.5 | 64.5 | 108 | 240 | 78.7 | 19.4 | 85.6 | 235 | 85.7 | 102 | 72.3 | 98.9 | 38.8 | 102 | 101 | 142 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.4 K | 1.22 | 134 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
169 | $ 9.21 | - | $ 596 M |  USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
20.6 | $ 0.87 | -2.13 % | $ 6.4 M | China |
 |
ACADIA Pharmaceuticals
ACAD
|
37.5 | $ 22.43 | 1.04 % | $ 3.72 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 3.06 | 2.34 % | $ 5.04 M |  Israel |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
Aquestive Therapeutics
AQST
|
103 | $ 4.08 | 0.83 % | $ 436 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
16.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
106 | $ 22.93 | 2.48 % | $ 2.92 B | USA |
 |
Edesa Biotech
EDSA
|
97.1 | $ 15.77 | -0.82 % | $ 50.4 M | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
58.2 | $ 1.43 | 1.06 % | $ 381 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | Israel |
 |
Evogene Ltd.
EVGN
|
30 | $ 0.76 | 0.71 % | $ 27.9 M | Israel |
 |
BioDelivery Sciences International
BDSI
|
115 | - | -4.8 % | $ 255 M | USA |
 |
Exelixis
EXEL
|
43.4 | $ 45.02 | 0.73 % | $ 12.2 B | USA |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |